

of Community Oriented Policing Services.

(4) *Affected public who will be asked or required to respond, as well as a brief abstract: Primary:* COPS Office hiring grantees that are selected for in-depth monitoring of their grant implementation and equipment grantees that report using COPS funds to implement a criminal intelligence system will be required to respond. The Monitoring Information Collections include two types of information collections: the Monitoring Request for Documentation and the 28 CFR Part 23 Monitoring Kit.

(5) *An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond/reply:* It is estimated that 140 respondents annually will complete the collections: 40 respondents to the Monitoring Request for Documentation at 3 hours per respondent; 100 respondents to the 28 CFR Part 23 Monitoring Kit at 2 hours per response.

(6) *An estimate of the total public burden (in hours) associated with the collection:* There are an estimated 320 total annual burden hours associated with this collection.

*If additional information is required contact:* Ms. Lynn Bryant, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Patrick Henry Building, Suite 1600, 601 D Street, NW., Washington, DC 20530.

Dated: August 23, 2006.

**Lynn Bryant,**

*Department Clearance Officer, PRA,  
Department of Justice.*

[FR Doc. E6-14280 Filed 8-28-06; 8:45 am]

**BILLING CODE 4410-AT-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[OMB Number 1117-0034]

#### Agency Information Collection Activities: Proposed Collection; Comments Requested

**ACTION:** 60-Day Notice of Information Collection Under Review: Collection of Laboratory Analysis Data on Drug Samples Tested by Non-Federal (State and Local Government) Crime Laboratories.

The Department of Justice (DOJ), Drug Enforcement Administration (DEA), has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with

the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. Comments are encouraged and will be accepted for "sixty days" until October 30, 2006. This process is conducted in accordance with 5 CFR 1320.10.

If you have comments, especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Mark W. Caverly, Chief, Liaison and Policy Section, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537.

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

- Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
- Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- Enhance the quality, utility, and clarity of the information to be collected; and
- Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

#### Overview of This Information Collection

(1) *Type of Information Collection:* Extension of a currently approved collection.

(2) *Title of the Form/Collection:* Collection of Laboratory Analysis Data on Drug Samples Tested by Non-Federal (State and Local Government) Crime Laboratories.

(3) *Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection: Form Number:* none. Office of Diversion Control, Drug Enforcement Administration, U.S. Department of Justice.

(4) *Affected public who will be asked or required to respond, as well as a brief abstract: Primary:* State, Local or tribal government. *Other:* None. *Abstract:*

Information is needed from state and local laboratories to provide DEA with additional analyzed drug information for the National Forensic Laboratory Information System.

(5) *An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:* It is estimated that there are one hundred fifty (150) total respondents for this information collection. One hundred twenty (120) respond monthly at .16 hour (10 minutes) for each response and thirty (30) respond quarterly at .16 hour (10 minutes) for each response, for a total number of 1560 respondents.

(6) *An estimate of the total public burden (in hours) associated with the collection:* It is estimated that there are 259 annual burden hours associated with this collection.

If additional information is required contact: Lynn Bryant, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Patrick Henry Building, Suite 1600, 601 D Street, NW., Washington, DC 20530.

Dated: August 23, 2006.

**Lynn Bryant,**

*Department Clearance Officer, U.S.  
Department of Justice.*

[FR Doc. E6-14278 Filed 8-28-06; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA-290P]

#### Controlled Substances: Proposed Aggregate Production Quotas for 2007

**AGENCY:** Drug Enforcement Administration (DEA), Justice.

**ACTION:** Notice of proposed year 2007 aggregate production quotas.

**SUMMARY:** This notice proposes initial year 2007 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act (CSA).

**DATES:** Comments or objections must be received on or before September 19, 2006.

**ADDRESSES:** To ensure proper handling of comments, please reference "Docket No. DEA-290P" on all written and electronic correspondence. Written comments being sent via regular mail should be sent to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537,

Attention: DEA **Federal Register** Representative/ODL. Written comments sent via express mail should be sent to DEA Headquarters, Attention: DEA **Federal Register** Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, VA 22301. Comments may be directly sent to DEA electronically by sending an electronic message to [dea.diversion.policy@usdoj.gov](mailto:dea.diversion.policy@usdoj.gov). Comments may also be sent electronically through <http://www.regulations.gov> using the electronic comment form provided on that site. An electronic copy of this document is also available at the <http://www.regulations.gov> Web site. DEA will accept attachments to electronic comments in Microsoft Word, WordPerfect, Adobe PDF, or Excel file formats only. DEA will not accept any file format other than those specifically listed here.

**FOR FURTHER INFORMATION CONTACT:** Christine A. Sannerud, Ph.D., Chief, Drug and Chemical Evaluation Section, Drug Enforcement Administration, Washington, DC 20537, Telephone: (202) 307-7183.

**SUPPLEMENTARY INFORMATION:** Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed

in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations. The Administrator, in turn, has redelegated this function to the Deputy Administrator, pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations.

The proposed year 2007 aggregate production quotas represent those quantities of controlled substances that may be produced in the United States in 2007 to provide adequate supplies of each substance for: the estimated medical, scientific, research, and industrial needs of the United States; lawful export requirements; and the establishment and maintenance of reserve stocks. These quotas do not include imports of controlled substances for use in industrial processes.

In determining the proposed year 2007 aggregate production quotas, the Deputy Administrator considered the following factors: total actual 2005 and estimated 2006 and 2007 net disposals of each substance by all manufacturers; estimates of 2006 year-end inventories of each substance and of any substance manufactured from it and trends in accumulation of such inventories; product development requirements of

both bulk and finished dosage form manufacturers; projected demand as indicated by procurement quota applications filed pursuant to Section 1303.12 of Title 21 of the Code of Federal Regulations; and other pertinent information.

Pursuant to Section 1303 of Title 21 of the Code of Federal Regulations, the Deputy Administrator of the DEA will, in early 2007, adjust aggregate production quotas and individual manufacturing quotas allocated for the year based upon 2006 year-end inventory and actual 2006 disposition data supplied by quota recipients for each basic class of Schedule I or II controlled substance.

Therefore, under the authority vested in the Attorney General by Section 306 of the CSA of 1970 (21 U.S.C. 826), and delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations, and redelegated to the Deputy Administrator pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations, the Deputy Administrator hereby proposes that the year 2007 aggregate production quotas for the following controlled substances, expressed in grams of anhydrous acid or base, be established as follows:

Basic class—schedule I	Proposed year 2007 quotas
2,5-Dimethoxyamphetamine .....	2,001,000 g
2,5-Dimethoxy-4-ethylamphetamine (DOET) .....	2 g
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) .....	10 g
3-Methylfentanyl .....	2 g
3-Methylthiofentanyl .....	2 g
3,4-Methylenedioxyamphetamine (MDA) .....	20 g
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) .....	10 g
3,4-Methylenedioxymethamphetamine (MDMA) .....	22 g
3,4,5-Trimethoxyamphetamine .....	2 g
4-Bromo-2,5-dimethoxyamphetamine (DOB) .....	2 g
4-Bromo-2,5-dimethoxyphenethylamine (2-CB) .....	7 g
4-Methoxyamphetamine .....	77 g
4-Methylaminorex .....	2 g
4-Methyl-2,5-dimethoxyamphetamine (DOM) .....	12 g
5-Methoxy-3,4-methylenedioxyamphetamine .....	2 g
5-Methoxy-N,N-diisopropyltryptamine .....	5 g
Acetyl-alpha-methylfentanyl .....	2 g
Acetyldihydrocodeine .....	2 g
Acetylmethadol .....	2 g
Allylprodine .....	2 g
Alphacetylmethadol .....	2 g
Alpha-ethyltryptamine .....	2 g
Alphameprodine .....	2 g
Alphamethadol .....	3 g
Alpha-methylfentanyl .....	2 g
Alpha-methylthiofentanyl .....	2 g
Alpha-methyltryptamine .....	5 g
Aminorex .....	2 g
Benzylmorphine .....	2 g
Betacetylmethadol .....	2 g
Beta-hydroxy-3-methylfentanyl .....	2 g
Beta-hydroxyfentanyl .....	2 g
Betameprodine .....	2 g

Basic class—schedule I	Proposed year 2007 quotas
Betamethadol	2 g
Betaprodine	2 g
Bufotenine	8 g
Cathinone	3 g
Codeine-N-oxide	302 g
Diethyltryptamine	2 g
Difenoxin	50 g
Dihydromorphine	2,549,000 g
Dimethyltryptamine	3 g
Gamma-hydroxybutyric acid	8,000,000 g
Heroin	5 g
Hydromorphanol	3,000 g
Hydroxypethidine	2 g
Lysergic acid diethylamide (LSD)	61 g
Marihuana	4,500,000 g
Mescaline	2 g
Methaqualone	10 g
Methcathinone	4 g
Methyldihydromorphine	2 g
Morphine-N-oxide	310 g
N,N-Dimethylamphetamine	7 g
N-Ethylamphetamine	2 g
N-Hydroxy-3,4-methylenedioxyamphetamine	2 g
Noracymethadol	2 g
Norlevorphanol	52 g
Normethadone	2 g
Normorphine	16 g
Para-fluorofentanyl	2 g
Phenomorphan	2 g
Pholcodine	2 g
Psilocybin	7 g
Psilocyn	7 g
Tetrahydrocannabinols	312,500 g
Thiofentanyl	2 g
Trimeperidine	2 g

Basic class—schedule II	Proposed year 2007 quotas
1-Phenylcyclohexylamine	2 g
Alfentanil	5,000 g
Alphaprodine	2 g
Amobarbital	2 g
Amphetamine	17,000,000 g
Cocaine	286,000 g
Codeine (for sale)	39,605,000 g
Codeine (for conversion)	55,000,000 g
Dextropropoxyphene	167,365,000 g
Dihydrocodeine	2,200,000 g
Diphenoxylate	828,000 g
Ecgonine	83,000 g
Ethylmorphine	2 g
Fentanyl	1,428,000 g
Glutethimide	2 g
Hydrocodone (for sale)	41,252,000 g
Hydrocodone (for conversion)	1,500,000 g
Hydromorphone	3,300,000 g
Isomethadone	2 g
Levo-alphaacetylmethadol (LAAM)	6 g
Levomethorphan	5 g
Levorphanol	6,000 g
Meperidine	9,753,000 g
Methadone (for sale)	25,000,000 g
Methadone Intermediate	26,000,000 g
Methamphetamine	3,130,000 g

[680,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2405,000 grams for methamphetamine mostly for conversion to a Schedule III product; and 45,000 grams for methamphetamine (for sale)]

Methylphenidate	35,000,000 g
Morphine (for sale)	35,000,000 g
Morphine (for conversion)	110,774,000 g

Basic class—schedule II	Proposed year 2007 quotas
Nabilone .....	2 g
Noroxymorphone (for sale) .....	1,002 g
Noroxymorphone (for conversion) .....	6,600,000 g
Opium .....	1,400,000 g
Oxycodone (for sale) .....	49,200,000 g
Oxycodone (for conversion) .....	2,600,000 g
Oxymorphone .....	1,500,000 g
Pentobarbital .....	28,000,000 g
Phencyclidine .....	2,021 g
Phenmetrazine .....	2 g
Racemethorphan .....	2 g
Remifentanyl .....	2,700 g
Secobarbital .....	2 g
Sufentanil .....	6,500 g
Thebaine .....	72,453,000 g

The Deputy Administrator further proposes that aggregate production quotas for all other Schedules I and II controlled substances included in Sections 1308.11 and 1308.12 of Title 21 of the Code of Federal Regulations be established at zero.

All interested persons are invited to submit their comments in writing or electronically regarding this proposal following the procedures in the **ADDRESSES** section of this document. A person may object to or comment on the proposal relating to any of the above-mentioned substances without filing comments or objections regarding the others. If a person believes that one or more of these issues warrant a hearing, the individual should so state and summarize the reasons for this belief.

In the event that comments or objections to this proposal raise one or more issues which the Deputy Administrator finds warrant a hearing, the Deputy Administrator shall order a public hearing by notice in the **Federal Register**, summarizing the issues to be heard and setting the time for the hearing.

The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866.

This action does not preempt or modify any provision of state law; nor does it impose enforcement responsibilities on any state; nor does it diminish the power of any state to enforce its own laws. Accordingly, this action does not have federalism implications warranting the application of Executive Order 13132.

The Deputy Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601 *et seq.* The establishment of aggregate production quotas for

Schedules I and II controlled substances is mandated by law and by international treaty obligations. The quotas are necessary to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and the establishment and maintenance of reserve stocks. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Accordingly, the Deputy Administrator has determined that this action does not require a regulatory flexibility analysis.

This action meets the applicable standards set forth in Sections 3(a) and 3(b)(2) of Executive Order 12988 Civil Justice Reform.

This action will not result in the expenditure by State, local, and tribal governments, in the aggregate, or by the private sector, of \$118,000,000 or more in any one year, and will not significantly or uniquely affect small governments. Therefore, no actions were deemed necessary under the provisions of the Unfunded Mandates Reform Act of 1995.

This action is not a major rule as defined by Section 804 of the Small Business Regulatory Enforcement Fairness Act of 1996. This action will not result in an annual effect on the economy of \$100,000,000 or more; a major increase in costs or prices; or significant adverse effects on competition, employment, investment, productivity, innovation, or on the ability of United States-based companies to compete with foreign-based companies in domestic and export markets.

Dated: August 22, 2006.

**Michele M. Leonhart,**  
*Deputy Administrator.*

[FR Doc. E6-14284 Filed 8-28-06; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF LABOR**

**Employment and Training Administration**

[TA-W-59,772]

**E.I. Dupont, Dupont Automotive Systems Division, Troy, MI; Notice of Termination of Investigation**

Pursuant to Section 221 of the Trade Act of 1974, as amended, an investigation was initiated on July 25, 2006 in response to a petition filed by a company official on behalf of workers at E.I. DuPont, DuPont Automotive Systems Division, Troy, Michigan. The workers at the subject facility produced automotive paints.

The petitioner has requested that the petition be withdrawn. Consequently, the investigation has been terminated.

Signed in Washington, DC, this 18th day of August, 2006.

**Richard Church,**

*Certifying Officer, Division of Trade Adjustment Assistance.*

[FR Doc. E6-14329 Filed 8-28-06; 8:45 am]

**BILLING CODE 4510-30-P**

**DEPARTMENT OF LABOR**

**Employment and Training Administration**

[TA-W-56,672A]

**Golden Northwest Aluminum, Inc., Northwest Aluminum Specialties Company, Currently Known as Northwest Aluminum Specialties, Inc., The Dalles, OR; Amended Certification Regarding Eligibility To Apply for Worker Adjustment Assistance and Alternative Trade Adjustment Assistance**

In accordance with Section 223 of the Trade Act of 1974 (19 U.S.C. 2273), and Section 246 of the Trade Act of 1974 (26